| Symbol | CLYM |
|---|---|
| Name | CLIMB BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 20 WILLIAM STREET,SUITE 145, WELLESLEY HILLS, Massachusetts, 02481, United States |
| Telephone | 1-866-857-2596 |
| Fax | — |
| — | |
| Website | https://www.climbbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001768446 |
| Description | Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Additional info from NASDAQ: |
New Form SCHEDULE 13D/A - Climb Bio, Inc. <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 0001346824-26-000189 <b>Size:</b> 24 KB
Read moreBrennan Aoife 🟡 adjusted position in 30.9K shares (1 derivative) of Climb Bio, Inc. (CLYM) at $13.17 Transaction Date: Jun 27, 2026 | Filing ID: 291131
Read more📋 AOIFE BRENNAN (Officer) plans to sell 31K shares of CLIMB BIO, INC. (at $13.17 each, total $407K) Filed: Jun 30, 2026 | ID: 291127
Read moreNew Form 424B5 - Climb Bio, Inc. <b>Filed:</b> 2026-06-12 <b>AccNo:</b> 0001193125-26-269510 <b>Size:</b> 457 KB
Read more(90% Positive) CLIMB BIO, INC. (CLYM) Announces Clinical Development Update
Read moreClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Read moreNew Form EFFECT - Climb Bio, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 9999999995-26-001931 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - Climb Bio, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001193125-26-263813 <b>Size:</b> 223 KB
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 40.0K shares (1 derivative) of Climb Bio, Inc. (CLYM) at $10.55 Transaction Date: Jun 05, 2026 | Filing ID: 000610
Read moreLevin Andrew David 🟢 acquired 40.0K shares (1 derivative) of Climb Bio, Inc. (CLYM) at $10.55 Transaction Date: Jun 05, 2026 | Filing ID: 262292
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07564596 | A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Phase1 | Systemic Lupus Erthematosus | Not_Yet_Recruiting | 2026-06-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT07248865 | A Phase 1 Study of CLYM116 in Normal Healthy Volunteers | Phase1 | Healthy Volunteers | Recruiting | 2025-12-02 | 2026-09-01 | ClinicalTrials.gov |
| NCT07096843 | A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | Phase2 | Primary Membranous Nephropathy | Recruiting | 2025-08-25 | 2027-10-01 | ClinicalTrials.gov |
| NCT07090655 | A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections … | Early_Phase1 | Healthy Volunteers | Completed | 2025-08-11 | 2026-04-07 | ClinicalTrials.gov |
| NCT07011043 | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2025-07-10 | 2027-04-01 | ClinicalTrials.gov |
| NCT07043946 | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | Phase1 | Immune Thrombocytopenia (ITP) | Recruiting | 2025-06-30 | 2028-08-01 | ClinicalTrials.gov |
| NCT05384041 | Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disord… | Na | Major Depressive Disorder | Completed | 2022-04-28 | 2022-10-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT07090655 |
| Budoprutug | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT07090655 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erthematosus | NOT_YET_RECRUITING | NCT07564596 |
| Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device) | Drug | Approved | Major Depressive Disorder | COMPLETED | NCT05384041 |
| Fisher Wallace Cranial Electrotherapy Stimulator (Active Device) | Drug | Approved | Major Depressive Disorder | COMPLETED | NCT05384041 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07248865 |
| CLYM116 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07248865 |
| Placebo | Other | Phase EARLY_PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07090655 |
| Budoprutug | Other | Phase EARLY_PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07090655 |
| Budoprutug | Other | Phase PHASE1 | Immune Thrombocytopenia (ITP) | RECRUITING | NCT07043946 |
| Budoprutug | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07011043 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| budoprutug | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| CLYM116 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07248865 |
| budoprutug | DRUG | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07096843 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07248865 |
| Budoprutug | DRUG | Phase EARLY_PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07090655 |